BACKGROUND: Coinfection with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) has emerged as a major cause of morbidity and mortality due to liver disease. Interferon-based therapy response rates have been disappointingly low. Baseline HCV complexity and the relationship between complexity and viral kinetic parameters has not been well described in HCV/HIV-coinfected subjects. METHODS: A subset of patients enrolled in the AIDS Clinical Trials Group 5071 trial underwent sampling to evaluate viral kinetics and changes in HCV complexity. Early kinetic parameters, baseline complexity, and treatment outcomes--including rapid viral response (RVR), early viral response (EVR), and sustained viral response (SVR)--were evaluated. HCV-monoinfected subjects were matched to HCV/HIV-coinfected subjects. RESULTS: Baseline complexity was determined in 108 HCV/HIV-coinfected subjects and in 13 HCV-monoinfected control subjects. Quasispecies complexity was a mean of 2.24 bands for HCV/HIV-coinfected subjects and a mean of 1.90 bands for HCV-monoinfected subjects (P = .14). Lower baseline complexity was associated with EVR (P = .04) and approached statistical significance for SVR. In patients who underwent viral kinetic modeling, a decrease in complexity was associated with RVR (P = .03) and was independent of the correlation between first-phase viral decline efficiency and RVR. CONCLUSION: Baseline HCV complexity is an independent predictor of EVR in HCV/HIV-coinfected subjects. A decrease in complexity occurs by 4 weeks after the initiation of interferon-based therapy and is associated with RVR. These findings may enhance the predictive modeling of treatment outcome in HCV/HIV-coinfected patients.
BACKGROUND: Coinfection with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) has emerged as a major cause of morbidity and mortality due to liver disease. Interferon-based therapy response rates have been disappointingly low. Baseline HCV complexity and the relationship between complexity and viral kinetic parameters has not been well described in HCV/HIV-coinfected subjects. METHODS: A subset of patients enrolled in the AIDS Clinical Trials Group 5071 trial underwent sampling to evaluate viral kinetics and changes in HCV complexity. Early kinetic parameters, baseline complexity, and treatment outcomes--including rapid viral response (RVR), early viral response (EVR), and sustained viral response (SVR)--were evaluated. HCV-monoinfected subjects were matched to HCV/HIV-coinfected subjects. RESULTS: Baseline complexity was determined in 108 HCV/HIV-coinfected subjects and in 13 HCV-monoinfected control subjects. Quasispecies complexity was a mean of 2.24 bands for HCV/HIV-coinfected subjects and a mean of 1.90 bands for HCV-monoinfected subjects (P = .14). Lower baseline complexity was associated with EVR (P = .04) and approached statistical significance for SVR. In patients who underwent viral kinetic modeling, a decrease in complexity was associated with RVR (P = .03) and was independent of the correlation between first-phase viral decline efficiency and RVR. CONCLUSION: Baseline HCV complexity is an independent predictor of EVR in HCV/HIV-coinfected subjects. A decrease in complexity occurs by 4 weeks after the initiation of interferon-based therapy and is associated with RVR. These findings may enhance the predictive modeling of treatment outcome in HCV/HIV-coinfectedpatients.
Authors: Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: P Farci; A Shimoda; A Coiana; G Diaz; G Peddis; J C Melpolder; A Strazzera; D Y Chien; S J Munoz; A Balestrieri; R H Purcell; H J Alter Journal: Science Date: 2000-04-14 Impact factor: 47.728
Authors: John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht Journal: Gastroenterology Date: 2002-10 Impact factor: 22.682
Authors: Hongxing Qin; Norah J Shire; Erica D Keenan; Susan D Rouster; M Elaine Eyster; James J Goedert; Margaret James Koziel; Kenneth E Sherman Journal: Blood Date: 2004-09-16 Impact factor: 22.113
Authors: Anu Osinusi; Aarthi Chary; Mark A Winters; Susanna Naggie; Henry Masur; Michael A Polis; Shyam Kottilil; Mark Holodniy Journal: J Med Virol Date: 2012-10 Impact factor: 2.327
Authors: Jason T Blackard; Gang Ma; Satarupa Sengupta; Christina M Martin; Eleanor A Powell; M Tarek Shata; Kenneth E Sherman Journal: J Med Virol Date: 2014-04-30 Impact factor: 2.327
Authors: Jason T Blackard; Gang Ma; Berkeley N Limketkai; Jeffrey A Welge; Peter D Dryer; Christina M Martin; Yoichi Hiasa; Lynn E Taylor; Kenneth H Mayer; Denise J Jamieson; Kenneth E Sherman Journal: J Clin Microbiol Date: 2010-09-01 Impact factor: 5.948
Authors: Jason T Blackard; Gang Ma; Jeffrey A Welge; Christina M Martin; Kenneth E Sherman; Lynn E Taylor; Kenneth H Mayer; Denise J Jamieson Journal: J Med Virol Date: 2012-02 Impact factor: 2.327
Authors: Iwona Bukowska-Ośko; Agnieszka Pawełczyk; Karol Perlejewski; Natalia Kubisa; Kamila Caraballo Cortés; Magdalena Rosińska; Rafał Płoski; Maria Fic; Justyna Kaźmierczak; Marta Popiel; Piotr Ząbek; Andrzej Horban; Marek Radkowski; Tomasz Laskus Journal: PLoS One Date: 2015-05-01 Impact factor: 3.240
Authors: Maria Homs; Francisco Rodriguez-Frias; Josep Gregori; Alicia Ruiz; Pilar Reimundo; Rosario Casillas; David Tabernero; Cristina Godoy; Salma Barakat; Josep Quer; Mar Riveiro-Barciela; Michael Roggendorf; Rafael Esteban; Maria Buti Journal: PLoS One Date: 2016-06-30 Impact factor: 3.240